Cargando…

A phase I and pharmacokinetic study of intraperitoneal topotecan

Purpose: To evaluate the feasibility and pharmacology of intraperitoneal (IP) topotecan. Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were treated with escalating IP topotecan doses (5–30 mg/m(2)) for pharmacokinetic analysis. Results: Dose limiting toxicit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hofstra, L S, Bos, A M E, Vries, E G E de, Zee, A G J van der, Beijnen, J H, Rosing, H, Mulder, N H, Aalders, J G, Willemse, P H B
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363984/ https://www.ncbi.nlm.nih.gov/pubmed/11742479 http://dx.doi.org/10.1054/bjoc.2001.2161

Ejemplares similares

Oral topotecan: bioavailability and effect of food co-administration
por: Herben, V M M, et al.
Publicado: (1999)

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks
por: Kerbusch, T, et al.
Publicado: (2004)

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996)

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
por: Jong, R S de, et al.
Publicado: (1999)

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer
por: Gelderblom, H, et al.
Publicado: (2001)

Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer
por: Bos, A M E, et al.
Publicado: (2000)

A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.
por: de Vries, E. G., et al.
Publicado: (1993)

DNA topoisomerase IIα and -β expression in human ovarian cancer
por: Withoff, S, et al.
Publicado: (1999)

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
por: Herben, V. M., et al.
Publicado: (1997)

Effect of intraperitoneally administered recombinant murine granulocyte-macrophage colony-stimulating factor (rmGM-CSF) on the cytotoxic potential of murine peritoneal cells
por: Klimp, A H, et al.
Publicado: (1999)

Factors affecting pharmacokinetic variability of oral topotecan: a population analysis
por: Léger, F, et al.
Publicado: (2004)

Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer
por: Gore, M, et al.
Publicado: (2001)

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.
por: Gietema, J. A., et al.
Publicado: (1995)

Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer
por: Levitt, N C, et al.
Publicado: (2005)

A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study
por: Fokkema, E, et al.
Publicado: (2000)

Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG)
por: Kuin, A, et al.
Publicado: (1999)

Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver
por: Vahrmeijer, A L, et al.
Publicado: (2000)

Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts.
por: Pratesi, G., et al.
Publicado: (1995)

Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation
por: Schröder, C P, et al.
Publicado: (2001)

Combining Isotopic Tracer Techniques to Increase Efficiency of Clinical Pharmacokinetic Trials in Oncology
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
por: Tellingen, O van, et al.
Publicado: (1999)

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001)

A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study
por: Frasci, G, et al.
Publicado: (2001)

Ovarian cysts in women receiving tamoxifen for breast cancer
por: Mourits, M J E, et al.
Publicado: (1999)

The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001)

A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin
por: Veal, G J, et al.
Publicado: (2001)

Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
por: Veldhuis, G. J., et al.
Publicado: (1997)

Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours
por: Thomson, A H, et al.
Publicado: (1999)

Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
por: de Jong, R. S., et al.
Publicado: (1997)

A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix
por: Wit, R de, et al.
Publicado: (1999)

Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study.
por: Groen, H. J., et al.
Publicado: (1995)

A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide.
por: McClay, E. F., et al.
Publicado: (1993)

Pharmacokinetics of Orbital Topotecan After Ophthalmic Artery Chemosurgery and Intravenous Infusion in the Swine Model
por: Requejo, Flavio, et al.
Publicado: (2023)

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin
por: Schoemaker, N E, et al.
Publicado: (2002)

A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer
por: Guppy, A E, et al.
Publicado: (2004)

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer
por: Terwogt, J M M, et al.
Publicado: (1999)

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours
por: Kerklaan, B Milojkovic, et al.
Publicado: (2015)

Carboplatin +/− Topotecan Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma
por: Francis, Jasmine H., et al.
Publicado: (2013)

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses
por: Keizer, Ron J, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g77u9vems1r1onphm4nr5diafm